KN-069

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NameKN-069
Drug Alias NameKN-069KN069
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionAnti-Glucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityMetabolic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Alphamab Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesXiamen Amoytop Biotech Co LtdSuzhou Alphamab Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityMetabolic Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A